6 posts in this category
FDA review finds no increased suicide risk with GLP-1 medications and is asking for related label warnings to be removed.
See how states, Medicare, Medicaid, and employer plans are handling GLP-1 coverage changes in 2026 and what it means for your insurance.
FDA: “many of the adverse events reported for compounded versions appear to be consistent with adverse events for the FDA‑approved products.”
We’ve all been hearing about the shortage of tirzepatide or semaglutide, but what is a shortage? How does it impact compounding?
The FDA has ended the shortage for tirzepatide, essential copy compounding ends on Feb 18 and March 19
OFA vs FDA Case Join report Nov 21
